Namiko Ikeda, Daiki Kato*, Masaya Tsuboi, Ryohei Yoshitake, Shotaro Eto, Sho Yoshimoto, Masahiro Shinada, Satoshi Kamoto, Yuko Hashimoto, Yousuke Takahashi, James Chambers, Kazuyuki Uchida, Ryohei Nishimura, Takayuki Nakagawa (* Corresponding author)


Cancer immunotherapy is a novel cancer treatment for canine tumors. Indoleamine 2,3-dioxygenase 1 (IDO1) is overexpressed in some human tumors and inhibits antitumor immunity. In this study, we comprehensively evaluated expression pattern of IDO1 and the nature of IDO1-expressing cells in canine normal and tumor tissues. In normal tissue samples, IDO1 expression was detected only in the lymph nodes, spleen, tonsil tissues, and colon tissues. In contrast, IDO1-positive tumor cells were observed in several tumor tissue types. This is the first study to evaluate IDO1 expression in canine normal and tumor tissues, and the results suggest that IDO1 is a promising target for novel cancer immunotherapy in dogs with tumors.

Paper Information

: The Journal of Veterinary Medical Science
: 10.1292/jvms.21-0217